TRACON Pharmaceuticals (TCON) IPO Opens Modestly Lower
Get Alerts TCON Hot Sheet
Join SI Premium – FREE
Today's IPO for TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) opened for trading at $9.90 after pricing 3,600,000 shares of common stock at a price to the public of $10.00 per share.
Wells Fargo Securities and Stifel are acting as joint book-running managers for the offering. Needham & Company, LLC and Oppenheimer & Co. Inc. are acting as co-managers.
TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rubrik, Inc. (RBRK) IPO Opens at $38.60, Priced at $32
- Marex Group (MRX) Prices 15.38M Share IPO at $19/sh
- Impinj Inc (PI) PT Raised to $160 at Needham
Create E-mail Alert Related Categories
IPOsRelated Entities
Needham & Company, Wells Fargo, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!